Scinai Immunotherapeutics Ltd - Asset Resilience Ratio
Scinai Immunotherapeutics Ltd (SCNI) has an Asset Resilience Ratio of 0.93% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Scinai Immunotherapeutics Ltd to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2016)
This chart shows how Scinai Immunotherapeutics Ltd's Asset Resilience Ratio has changed over time. See SCNI net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Scinai Immunotherapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SCNI market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $138.01K | 0.93% |
| Total Liquid Assets | $138.01K | 0.93% |
Asset Resilience Insights
- Limited Liquidity: Scinai Immunotherapeutics Ltd maintains only 0.93% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Scinai Immunotherapeutics Ltd Industry Peers by Asset Resilience Ratio
Compare Scinai Immunotherapeutics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Scinai Immunotherapeutics Ltd (2008–2016)
The table below shows the annual Asset Resilience Ratio data for Scinai Immunotherapeutics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2016-12-31 | 31.98% | $2.50 Million | $7.82 Million | +27.10pp |
| 2015-12-31 | 4.88% | $517.39K | $10.60 Million | -6.04pp |
| 2014-12-31 | 10.92% | $517.41K | $4.74 Million | +3.12pp |
| 2013-12-31 | 7.80% | $580.52K | $7.45 Million | -16.23pp |
| 2012-12-31 | 24.03% | $1.50 Million | $6.22 Million | -35.10pp |
| 2011-12-31 | 59.13% | $4.24 Million | $7.16 Million | -16.19pp |
| 2010-12-31 | 75.32% | $6.54 Million | $8.68 Million | -11.25pp |
| 2009-12-31 | 86.57% | $7.75 Million | $8.95 Million | -0.34pp |
| 2008-12-31 | 86.92% | $2.78 Million | $3.20 Million | -- |
About Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's s… Read more